The Drug That Just Dethroned a Bile Duct Cancer King
Akeso's ivonescimab just beat the reigning first-line standard in biliary tract cancer in a head-to-head Phase 3 trial, marking the first time any drug has toppled a checkpoint inhibitor combo in this disease. Wall Street is paying attention, and the implications stretch well beyond bile ducts.
Bile duct cancer is one of the nastiest diagnoses in oncology. Median survival hovers around a year, even with the best available treatment. The first-line standard of care has been locked in since 2022, when a drug called durvalumab proved it could extend life by a modest but meaningful margin.
Nobody expected that standard to fall this fast.
On Tuesday, Chinese biotech Akeso announced that its drug ivonescimab beat durvalumab head-to-head in a Phase 3 trial for first-line advanced biliary tract cancer (BTC). The study, called HARMONi-GI1, hit its primary endpoint of overall survival at a pre-specified interim analysis. It also swept the key secondary endpoints: progression-free survival (how long patients lived without tumors growing) and objective response rate (how many tumors actually shrank).
This appears to be the first Phase 3 trial ever reported to show a statistically significant survival benefit over a PD-L1 inhibitor plus chemotherapy in this disease. That's not incremental. That's a regime change.
The Old Guard: How Durvalumab Got Its Crown
To understand why this matters, you need to know the backstory. Biliary tract cancer includes cancers of the bile ducts and gallbladder, and treatment options have historically been grim. For years, the playbook was gemcitabine plus cisplatin (a standard chemo combo) and not much else.
Then came TOPAZ-1, the Phase 3 trial that changed the landscape. It showed that adding durvalumab (AstraZeneca's checkpoint inhibitor, sold as Imfinzi) to that same chemo backbone improved median overall survival from 11.3 months to 12.9 months. The hazard ratio was 0.76, meaning durvalumab cut the risk of death by about 24%.
That might not sound like a lot, but in bile duct cancer, it was genuinely practice-changing. The two-year survival rate more than doubled: 24.9% with durvalumab versus just 10.4% without. Durvalumab became the new king. Oncologists adopted it worldwide. The case seemed closed.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A Two-for-One Antibody
Ivonescimab isn't just another checkpoint inhibitor. It's a bispecific antibody, which means it grabs two different targets at once: PD-1 (an immune checkpoint that tumors exploit to hide from the immune system) and VEGF-A (a protein that tumors use to grow new blood vessels and feed themselves).
Think of it like a bouncer who can simultaneously kick out the guy sneaking in the back door and cut off the supply truck pulling up to the loading dock. One molecule, two jobs.
What makes ivonescimab particularly clever is something called cooperative binding. When it latches onto VEGF, its grip on PD-1 gets tighter, and vice versa. The two mechanisms reinforce each other in the tumor neighborhood, creating a feedback loop that single-target drugs can't replicate.
The underlying logic is sound: tumors are complex systems. Blocking one pathway often isn't enough because cancer finds workarounds. Hitting both the immune escape route and the blood supply simultaneously could explain why ivonescimab seems to outperform a drug that only tackles one of those problems.
The Trial That Changes the Conversation
HARMONi-GI1 was a randomized, controlled, multicenter Phase 3 trial comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy in treatment-naive advanced BTC patients, with survival as the primary endpoint.
Akeso described the results as "clinically meaningful and statistically significant" across the board. The company hasn't yet released the specific numbers (those are being saved for a medical conference presentation and journal publication), so we don't have a hazard ratio or median survival figure to chew on.
That's a notable gap. In biotech, "trust us, it worked" only goes so far. The market and the medical community will want to see just how much better ivonescimab performed. A hazard ratio of 0.85 tells a very different story than 0.65. The devil, as always, is in the decimals.
Still, the fact that the trial met its primary endpoint at an interim analysis is encouraging. Interim looks are designed to have higher statistical bars, which means the survival difference had to be convincing enough to clear a tougher threshold.
Wall Street Noticed
The readout sent positive ripples through the investment community. Guggenheim reiterated a Buy rating on Summit Therapeutics (which partners with Akeso on ivonescimab outside China) and maintained a $38 price target, calling the BTC win a boost to confidence in the drug's broader platform.
Bernstein SocGen went a step further, upgrading Summit from Underperform to Market Perform and bumping the price target to $11.90 from $9.80. Even Bernstein's caution was telling; they remain skeptical about ivonescimab becoming a true Keytruda replacement across all tumor types, but acknowledged the data was getting harder to ignore.
The broader thesis at play: cross-tumor consistency. Ivonescimab has now shown clinical activity in non-small cell lung cancer (with a striking PFS win over pembrolizumab, showing 11.1 versus 5.8 months), in EGFR-mutant lung cancer after targeted therapy failure, and now in bile duct cancer. That pattern matters. Drugs that work across multiple tumor types tend to become big commercial franchises.
The Bigger Picture (and the Bigger Questions)
Biliary tract cancer remains a brutal disease. Even with durvalumab, most patients don't survive two years. The pipeline is crowded with experimental combinations (dual checkpoint blockers, bispecifics targeting TIGIT, antiangiogenic combos), but nothing has yet cracked the code for durable long-term survival.
Ivonescimab's win is real, but questions remain. How large was the survival benefit? Will it hold up in Western patient populations, where regulatory agencies like the FDA will want to see confirmatory data? And can Akeso and Summit navigate the commercial and regulatory path quickly enough to capitalize?
The last question is especially relevant because ivonescimab's biggest prize isn't bile duct cancer; it's lung cancer, the largest oncology market in the world. The BTC result functions as a proof-of-concept appetizer. If the drug can beat an entrenched standard in one tough tumor, maybe the broader oncology thesis has legs.
For now, the scoreboard reads: ivonescimab 1, durvalumab 0 in bile duct cancer. The full data will determine whether that scoreline holds. But one thing is clear: the era of assuming durvalumab's position in BTC was untouchable just ended.
Deals & M&A
4 min read
Vertex Just Bet $10 Billion That It's Not a One-Trick Pony
Vertex Pharmaceuticals just dropped $10 billion on Crinetics Pharmaceuticals, its largest acquisition ever, paying a 102% premium to snap up a rare endocrine disease platform. The deal is a massive bet that Vertex can reinvent itself beyond cystic fibrosis, and Wall Street has opinions.
